Literature DB >> 23503460

The regulatory roles of phosphatases in cancer.

J Stebbing1, L C Lit1, H Zhang1, R S Darrington1, O Melaiu1, B Rudraraju1, G Giamas1.   

Abstract

The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3-kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503460     DOI: 10.1038/onc.2013.80

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  Adaptation of HepG2 cells to a steady-state reduction in the content of protein phosphatase 6 (PP6) catalytic subunit.

Authors:  Joan M Boylan; Arthur R Salomon; Umadevi Tantravahi; Philip A Gruppuso
Journal:  Exp Cell Res       Date:  2015-05-18       Impact factor: 3.905

Review 2.  Long Non-coding RNAs and their Role in Metastasis.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwen Kollmorgen; Rüdiger Rüger
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

3.  FANCI is a negative regulator of Akt activation.

Authors:  Xiaoshan Zhang; Xiaoyan Lu; Shamima Akhter; Maria-Magdalena Georgescu; Randy J Legerski
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.

Authors:  T Tao; X Yang; J Zheng; D Feng; Q Qin; X Shi; Q Wang; C Zhao; Z Peng; H Liu; W G Jiang; J He
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 5.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

6.  Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion.

Authors:  M P Ward; J P Spiers
Journal:  Br J Pharmacol       Date:  2017-04-07       Impact factor: 8.739

Review 7.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

8.  The PTEN/NRF2 axis promotes human carcinogenesis.

Authors:  Ana I Rojo; Patricia Rada; Marta Mendiola; Ana Ortega-Molina; Katarzyna Wojdyla; Adelina Rogowska-Wrzesinska; David Hardisson; Manuel Serrano; Antonio Cuadrado
Journal:  Antioxid Redox Signal       Date:  2014-07-31       Impact factor: 8.401

Review 9.  Tissue-specific tumorigenesis: context matters.

Authors:  Günter Schneider; Marc Schmidt-Supprian; Roland Rad; Dieter Saur
Journal:  Nat Rev Cancer       Date:  2017-03-03       Impact factor: 60.716

10.  Identification of key gene signatures for the overall survival of ovarian cancer.

Authors:  Akash Pawar; Oindrila Roy Chowdhury; Ruby Chauhan; Sanjay Talole; Atanu Bhattacharjee
Journal:  J Ovarian Res       Date:  2022-01-20       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.